242 related articles for article (PubMed ID: 21443205)
1. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
[TBL] [Abstract][Full Text] [Related]
2. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
[TBL] [Abstract][Full Text] [Related]
4. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
5. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
9. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of pyrazolo[4,3-d]pyrimidine analogues.
Yuan L; Song C; Li C; Li Y; Dong L; Yin S
Eur J Med Chem; 2013 Sep; 67():152-7. PubMed ID: 23851116
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anticancer effects of some novel pyrazolo[3,4-d]pyrimidine derivatives by generating reactive oxygen species in human breast adenocarcinoma cells.
Rashad AE; Mahmoud AE; Ali MM
Eur J Med Chem; 2011 Apr; 46(4):1019-26. PubMed ID: 21315495
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
Ciciani G; Coronnello M; Guerrini G; Selleri S; Cantore M; Failli P; Mini E; Costanzo A
Bioorg Med Chem; 2008 Nov; 16(21):9409-19. PubMed ID: 18845441
[TBL] [Abstract][Full Text] [Related]
14. Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
Antonini I; Polucci P; Magnano A; Sparapani S; Martelli S
J Med Chem; 2004 Oct; 47(21):5244-50. PubMed ID: 15456268
[TBL] [Abstract][Full Text] [Related]
15. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
16. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel pyrazoles and pyrazolo[3,4-d]pyrimidines incorporating a benzenesulfonamide moiety.
Ashour HM; Wahab AE
Arch Pharm (Weinheim); 2009 Apr; 342(4):238-52. PubMed ID: 19340837
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiproliferative activity in vitro of new 2-, 3- or 4-substituted pyrido[2',3':3,4]pyrazolo[1, 5-a]pyrimidines.
Poreba K; Wietrzyk J; Opolski A
Acta Pol Pharm; 2006; 63(3):189-94. PubMed ID: 20085223
[TBL] [Abstract][Full Text] [Related]
20. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
